Krystal Biotech (NASDAQ:KRYS) CAO Kathryn Romano Sells 750 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano sold 750 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total value of $200,700.00. Following the completion of the transaction, the chief accounting officer directly owned 22,366 shares in the company, valued at $5,985,141.60. This trade represents a 3.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Kathryn Romano also recently made the following trade(s):

• On Monday, February 9th, Kathryn Romano sold 12,500 shares of Krystal Biotech stock. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $263.80 on Wednesday. The business has a 50-day moving average of $269.38 and a two-hundred day moving average of $216.90. The firm has a market capitalization of $7.71 billion, a PE ratio of 38.51 and a beta of 0.49. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to analyst estimates of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on KRYS shares. HC Wainwright reissued a “buy” rating and issued a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Citigroup increased their price target on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 18th. Bank of America boosted their price objective on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Chardan Capital increased their target price on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $326.25.

Institutional Trading of Krystal Biotech

Large investors have recently modified their holdings of the business. Soleus Capital Management L.P. lifted its stake in shares of Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Braidwell LP increased its holdings in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after purchasing an additional 327,067 shares during the last quarter. Norges Bank purchased a new stake in Krystal Biotech during the 4th quarter worth approximately $70,159,000. William Blair Investment Management LLC raised its position in shares of Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after purchasing an additional 227,038 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Krystal Biotech by 2,078.9% during the 4th quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after buying an additional 209,369 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.